CAMP · CAMP4 Therapeutics Corporation

Summary

CAMP4 Therapeutics Corporation appointed Michael MacLean as a Class III director effective April 1, 2026, increasing the Board size from eight to nine members. He was also appointed to the Audit Committee and Compensation Committee, and will receive an option to purchase 56,000 shares of common stock vesting monthly over three years under the amended Non-Employee Director Compensation Policy.

Key takeaways

• Board appointed Michael MacLean, age 60, as Class III director effective 2026-04-01.
• Board size increased from 8 to 9 members on March 18, 2026.
• Mr. MacLean appointed to Audit Committee and Compensation Committee effective 2026-04-01.
• Granted option for 56,000 shares under 2024 Equity Incentive Plan, vesting monthly over 3 years.
• Amended Non-Employee Director Compensation Policy for new directors on or after 2026-04-01.